New Russian Trivalent Hepatitis B Vaccine (Bubo^®-Unigep): Clinical Study Results

Relevance. Currently, there is no registered vaccine against the hepatitis B virus (HBV) mutant G145R worldwide, which justifies the need to develop a new generation of vaccines due to large-scale immunization against hepatitis B and the accumulation of escape mutants of the virus.

The aim of the study was a comparative assessment of the immunogenicity, reactogenicity and safety of Bubo®-Unigep (trivalent hepatitis B recombinant yeast vaccine) and the drug Hepatitis B recombinant yeast vaccine.

Materials and methods. To assess the main characteristics of the new trivalent vaccine Bubo®-Unigep (CJSC NPC «COMBIOTECH»), a doubleblind, comparative, randomized, multicenter clinical trial was conducted in two parallel groups in previously unvaccinated individuals in an adult healthy population (n = 166) according to a protocol developed by the contract research organization «R&D Pharma».

Results. The assessment of hematological and biochemical parameters during screening and the administration of vaccine preparations showed that in the individuals included in the study, the studied indicators were within the boundaries of the normal range. According to the criteria for assessing safety and efficacy, both drugs had low reactogenicity, no serious adverse events were registered. The results of a comparative analysis of the concentrations of antibodies to HBsAg determined after a full course of immunization with Bubo®-Unigep vaccine or recombinant yeast Hepatitis B vaccine showed that both drugs effectively induced a humoral immune response (anti-HBs) with seroprotection rates of 96.3% and 92.6%.

Conclusion. The inclusion of the relevant HBV serotypes (ay and ad) and the mutant antigen G145R in the composition of the new polyvalent vaccine Bubo®-Unigep contributes to the expansion of the spectrum of specificity of the immune response, and, consequently, more effective vaccination of hepatitis B.

1. Hepatitis B. Key facts. 24 June 2022. Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b (accessed May 30, 2023).

2. Documentation of WHO for Executive Board sessions and Health Assemblies. WHA75. May 2022. Available at: https://apps.who.int/gb/e/e_wha75.html (accessed June 2, 2023).

3. On the state of sanitary and epidemiological welfare of the population in the Russian Federation in 2021: State Report. Moscow: Federal Service for Supervision of Consumer Rights Protection and Human Well-being. 2022.– 340 p. (in Russ.).

4. Coffin, C.S., Osiowy, C., Gao, S., et al. Hepatitis B virus (HBV) variants fluctuate in paired plasma and peripheral blood mononuclear cells among patient cohorts during different chronic hepatitis B (CHB) disease phases. J. Viral Hepat. 2015;22(4):416–426. https://doi.org/10.1111/jvh.12308

5. Konopleva, M.V., Borisova, V.N. Sokolova, M.V, et al. Recombinant HBsAg of theWild-Type and the G145R Escape Mutant, included in the New Multivalent Vaccine against Hepatitis B Virus, Dramatically Differ in their Effects on Leukocytes from Healthy Donors In Vitro. Vaccines. 2022;10:235. https://doi.org/10.3390/vaccines10020235 Hepatitis B Virus, Dramatically Differ in their

6. Akimkin V.G., Semenenko T.A. Epidemiological and immunological efficacy of health workers vaccination against hepatitis B. Epidemiology and Vaccinal Prevention. 2017; 4 (95):52–57 (In Russ.). https://doi.org/10.31631/2073-3046-2017-16-4-52-57

7. Kochetova E.O., Shamsheva O.V., Polesko I.V., et al. Features of the formation of specific immunity after vaccination against viral hepatitis B in children and young people. Attending physician. 2023; 7-14. DOI: 10.51793/OS.2023.26.6.001.

8. Semenenko T.A. Immune response after vaccination against hepatitis B in patients with immunodeficiency. Epidemiology and Vaccinal Prevention. 2011;1(56):51–58 (In Russ.)

9. Chulanov V.P., Semenenko T.A., Karandashova I.V., et al. Modern View on the Problem of Choosing a Vaccine against Hepatitis B. Epidemiology and Vaccinal Prevention. 2017;16(4):65–72 (In Russ.). https://doi.org/10.31631/2073-3046-2017-16-4-65-72

10. Semenenko T.A., Yarosh L.V., Bazhenov A.I., et al. Epidemiological assessment of the prevalence of «occult» forms and HBsAg mutants of hepatitis B virus in hematological patients. Epidemiology and Vaccinal Prevention. 2012;6 (67):9–14 (In Russ.).

11. Krymsky M. A., Krymsky R. M., Budanov M. V., et al. Compliance of hepatitis B vaccines with the type of virus prevailing on the territory of the Russian Federation. Biopharmaceutical Journal. 2010;2(5):8–15.

12. Sokolova, M.V.. Konopleva, M.V., Semenenko, T.A.; Akimkin, V.G.; Tutelyan, A.V.; Suslov, A.P. The mechanisms of immune escape by hepatitis B virus. Ann. Russ. Acad. Med. Sci. 2017, 72 (6), 408–419. (In Russ.). https://doi.org/10.15690/vramn866

13. Konopleva M.V., Borisova V.N., Semenenko T.A., Krymskij M.A. Problems of the Current Vaccination Strategy against Hepatitis B. Epidemiology and Vaccinal Prevention. 2017;16(4):58–63 (In Russ.) https://doi.org/10.31631/2073-3046-2017-16-4-58-63

14. Asatryan M.N., Salman E.R., Kilikovsky V.V., et al. The study of the processes of the spread of mutant variants of the «vaccine flight» of the hepatitis B virus using a computer epidemiological model. Epidemiology and infectious diseases. Current issues. 2013;6: 34–38.

15. Konopleva M.V., Borisova V.N., Sokolova M.V., et al. Comparative characteristics of the antigenic properties of recombinant and native HBs antigens with the G145R mutation and an assessment of their immunogenicity. Problems of virology. 2017; 62 (4): 179-186. https://doi.org/10.18821/0507-4088-2017-62-4-179-186

16. Maksvitis RY, Ivanov RV, Amelin AV, et al. New Russian Trivalent Hepatitis B vaccine (Bubo®-Unigep): Phase I Clinical Study Results and Perspectives of Further Investigations Aiming Registration in Russia. Epidemiology and Vaccinal Prevention. 2019;18(6):45–52 (In Russ.). https://doi.org/10.31631/2073-3046-2019-18-6-45-52

17. Tseng TC, Yang HC, Kao JH. More viral mutants, less HBsAg clearance? One size may not fit all. Gut. 2017;66(7):1349. doi: 10.1136/gutjnl-2016-313027.

18. Lazarevic I, Banko A, Miljanovic D, Cupic M. Immune-Escape Hepatitis B Virus Mutations Associated with Viral Reactivation upon Immunosuppression. Viruses. 2019;11(9):778. doi: 10.3390/v11090778.